Multivariate regression analysis was further used, combined with other factors that may influence NAT efficacy including T stage, N stage, Ki67, BC molecular subtypes, etc. Results indicated that CD3+ T cell (OR 1.11, 95% CI 1.03–1.21, p = 0.01), CD8+ T cells (OR1.09, 95% CI 1.02–1.18, p = 0.02), and NK cells (OR 0.91, 95% CI 0.83–0.98, p = 0.03) were independent predictors of pCR in BC patients (Figure 6) (Table3). This evidence concerns the gene CD8A and breast cancer.